Week In Review: China’s Luxin Invests In 5 Million Funding For Intarcia’s Long-Term Diabetes …

Deals and Financings Luxin Venture Capital (SHA: 600783) of Shandong Province participated in the first closing of the latest funding round for Boston’s Intarcia Therapeutics. Intarcia is developing a novel delivery device for type 2 diabetes, the Medici Drug Delivery System™. The initial close raised $215 million. Intarcia anticipates a much larger close in Q4. Intarcia has completed three Phase III trials of its matchstick-sized implantable device that metes out a year-long supply of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Aspen Pharmacare, a South African generic drugmaker, paid GlaxoSmithKline (NYSE:GSK) $60 million for rights to sell two thrombosis drugs in China, India and Pakistan. Aspen originally acquired rights in most countries to the drugs – Fraxiparine and Arixtra – three years ago. The latest rights deal came in addition…


Link to Full Article: Week In Review: China’s Luxin Invests In 5 Million Funding For Intarcia’s Long-Term Diabetes …

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!